Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cemm - Forschungszentrum Für Molekulare Medizin GmbH has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. HAVLIN, ROBERT H is the busiest examiner, overseeing 1 pending office action. The presence of 2 distinct art units for 2 pending actions indicates that each matter is being reviewed in a different technical section.
This distribution requires the company to manage 2 distinct examiner relationships simultaneously. The fact that each of the 2 distinct examiners handles 1 pending office action suggests that no single individual dominates the current workload. Practitioners must adapt their strategies to the specific requirements of 2 different art units within the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641048 | METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES | CASH, KAILEY ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562029 | 1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE-BASED SLC16A3 INHIBITORS AND THEIR THERAPEUTIC USE | HAVLIN, ROBERT H | 36d |
| 17641048 | METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES | CASH, KAILEY ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562029 | 1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE-BASED SLC16A3 INHIBITORS AND THEIR THERAPEUTIC USE | HAVLIN, ROBERT H | 1626 | §112 | Final Rejection | 36d | Pending | Nov 17, 2023 |
| 17641048 | METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Final Rejection | — | Pending | Sep 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial